ophthalmology

ARCA biopharma Notice of Allowance obtained for patent for the treatment of patients with heart failure, bucindolol on genetic testing BasedARCA Biopharma , a biopharmaceutical company , which was genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that there is a Notice of Allowance from the U.S. Patent and Trademark Office received for their U.S. Patent application No. 908, entitled method for treatment with bucindolol based Genetic targeting. The Notice of Allowance is the USPTO ‘s official announcement that the examination of the patent application has been successfully completed and that a patent be granted. After the issue of patent protection for methods of treating heart failure patients with bucindolol based on genetic testing will.

Found found at the reaction to certain medications, the guidelines do not refer the presentation of most other data from genetic testing FDA would voluntarily submission of data from genetic tests used for scientific and informational purposes (Wall Street Journal.. Deputy commissioner be encouraged to gather Drug Companies, submit genetic data with Medication applicationsOther Reaction Edward Abraham – Managing Director of the Personalized Medicine Coalition, businesses, academic institutions and others , which includes promoting the field – praised the Guidelines added: added: the government is now the lawyer for personalized medicine in an official way. Continue reading

Page 6 of 6« First...23456